Palomar entering skin resurfacing laser market with Tissue Technologies buy.
This article was originally published in The Gray Sheet
Executive SummaryPALOMAR PLANS TO ENTER SKIN RESURFACING LASER MARKET VIA ACQUISITION of Tissue Technologies, Inc. outlined in an agreement in principle signed Feb. 9. Privately held Tissue Technologies said the stock swap acquisition is valued in the $20-30 mil. range. Specific terms of the deal, expected to close by mid- March, were not disclosed.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.